V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220021574 | 220018165 | null | null | Curative (C) | 2016-01-25 | 2016-01-25 | Cytarabine+Methotrexate Intrathecal | null | null | 220035329 | SPANISH MAINTENANCE |
| 220021575 | 220014964 | null | 48.1 | Palliative (P) | 2013-07-14 | 2013-07-14 | MYELOMA XI TRIAL | Y | null | 220035347 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220021576 | 220009361 | 1.85 | 78.2 | Curative (C) | 2018-04-19 | 2018-04-24 | Lenalidomide 25mg (Cycle 1 to 25) | N | N | 220035373 | RAVVA TRIAL |
| 220021577 | 220009364 | 1.7 | 95.5 | Palliative (P) | null | 2018-03-06 | Alemtuzumab+Busulfan+CyclophosphMUD | N | N | 220035392 | BUSULFAN + CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021578 | 220009368 | 1.67 | 60 | Curative (C) | 2017-08-09 | 2017-08-09 | PEMBROLIZUMAB | N | N | 220035406 | VINORELBINE |
| 220021579 | 220009373 | 1.67 | 65.8 | Curative (C) | 2016-04-15 | 2016-04-15 | BUSULFAN + MELPHALAN | 2 | N | 220035412 | DABRAFENIB |
| 220021580 | 220009379 | null | 102.4 | Palliative (P) | 2014-10-10 | 2014-10-10 | CAV | N | N | 220035414 | DABRAFENIB + TRAMETINIB |
| 220021582 | 220009410 | 1.57 | 50.3 | Curative (C) | 2015-08-14 | 2015-10-05 | Capecitabine | N | N | 220035549 | UKALL60+ |
| 220021583 | 220009414 | null | 64.9 | Curative (C) | null | 2018-03-31 | Etoposide oral | N | N | 220035566 | ARSENIC TRIOXIDE + ATRA |
| 220021584 | 220009425 | 1.68 | 45 | Curative (C) | null | 2015-03-14 | OSIMERTINIB | N | null | 220035632 | FLUDARABINE |
| 220021585 | 220015002 | 1.6 | 76 | Disease modification (D) | 2015-09-29 | 2015-10-04 | RAVVA TRIAL | 02 | N | 220035672 | DACTINOMYCIN |
| 220021587 | 220018196 | 1.71 | 80 | Disease modification (D) | null | 2015-02-14 | CARFILZOMIB | 01 | N | 220035925 | ARSENIC TRIOXIDE |
| 220021588 | 220009475 | null | null | Curative (C) | 2017-10-07 | 2017-11-07 | Depocyte Intrathecal | N | N | 220035947 | UKALL2011 |
| 220021589 | 220009493 | 1.56 | 68 | Palliative (P) | 2015-06-09 | 2015-06-10 | DABRAFENIB + TRAMETINIB | 01 | N | 220036034 | LENALIDOMIDE |
| 220021590 | 220009500 | 1.64 | 89 | Curative (C) | 2016-04-04 | 2016-04-04 | MACE | 02 | N | 220036062 | CAPECITABINE |
| 220021591 | 220009510 | 1.55 | 68.3 | Curative (C) | 2015-12-20 | 2015-12-24 | CYTARABINE + MITOXANTRONE | 01 | N | 220036121 | GANETESPIB |
| 220021593 | 220021928 | 1.6 | 78.4 | Curative (C) | 2017-11-08 | 2017-11-08 | Ipilimumab | 02 | N | 220036280 | CETUXIMAB + RT |
| 220021594 | 220009579 | 1.74 | 44.4 | null | 2018-08-07 | 2018-08-13 | ALL Int Guide A/B/C Maint Ph V | N | N | 220036432 | FLUOROURACIL |
| 220021595 | 220009595 | null | 72.5 | Curative (C) | 2017-05-18 | 2017-05-30 | GCLAC | N | N | 220036524 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220021597 | 220009621 | null | null | Curative (C) | 2014-10-09 | 2014-10-09 | ALEMTUZUMAB + FLUDARABINE | N | N | 220036606 | CISPLATIN |
| 220021598 | 220009642 | 1.64 | 64.3 | Disease modification (D) | 2015-03-29 | 2015-04-06 | Trastuzumab 21 day maintenance | N | N | 220036641 | CAPECITABINE + OXALIPLATIN |
| 220021599 | 220015100 | null | 78.8 | Curative (C) | null | 2018-08-29 | ALL Int Gde A/B DInt PhIV pt1 PAsp | 2 | N | 220036683 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220021600 | 220009682 | 1.75 | 68.45 | null | 2012-10-15 | 2014-01-12 | VINORELBINE | 2 | N | 220000653 | FIGARO TRIAL |
| 220021601 | 220009685 | 1.71 | 78 | Curative (C) | 2016-07-25 | 2016-07-26 | Sorafenib | 02 | N | 220002814 | LENALIDOMIDE |
| 220021602 | 220009691 | 1.83 | 69 | Curative (C) | 2017-07-14 | 2017-11-10 | VINORELBINE | 02 | N | 220004682 | MITOXANTRONE + TRETINOIN |
| 220021603 | 220015121 | 1.64 | 48.8 | null | 2018-12-01 | 2019-01-08 | MACE | N | N | 220014128 | CAPECITABINE + OXALIPLATIN |
| 220021604 | 220009715 | null | 103.4 | Palliative (P) | 2017-12-25 | 2018-07-06 | R GCVP | N | null | 220018242 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220021605 | 220009744 | null | null | Curative (C) | 2015-10-29 | 2015-11-02 | Cytarabine+Methotrexate Intrathecal | null | N | 220022881 | MELPHALAN |
| 220021606 | 220009775 | null | null | Curative (C) | 2019-08-04 | 2019-10-27 | MITOMYCIN | 01 | N | 220029686 | FIGARO TRIAL |
| 220021607 | 220009783 | null | 112.4 | Curative (C) | 2018-03-29 | 2018-03-29 | Etoposide IV | N | null | 220032124 | CARBOPLATIN + RT |
| 220021608 | 220009786 | null | 81.3 | Disease modification (D) | 2018-09-05 | 2018-12-15 | MITOXANTRONE + TRETINOIN | 02 | N | 220032395 | CYTARABINE IT + METHOTREXATE |
| 220021609 | 220009796 | 1.63 | 63 | Curative (C) | 2015-07-13 | 2015-07-24 | MACE | N | N | 220034048 | PEMBROLIZUMAB |
| 220021610 | 220009806 | 0 | 126 | Curative (C) | 2015-07-08 | 2015-07-08 | Arsenic Triox + Tretinoin Ind W1-4 | 2 | N | 220034508 | BUSULPHAN + CYCLO |
| 220021611 | 220009813 | 1.6 | 66 | null | 2017-09-18 | 2017-09-18 | Midostaurin | 2 | N | 220035216 | FCR |
| 220021612 | 220009830 | 1.6 | 56.5 | Disease modification (D) | 2019-06-21 | 2019-10-10 | CHOP - 21 days | 2 | N | 220026545 | ETOPOSIDE |
| 220021613 | 220004062 | null | 78.5 | Disease modification (D) | 2016-12-29 | 2017-01-05 | IMATINIB | N | N | 220000242 | IMATINIB |
| 220021615 | 220004071 | 1.83 | 78.5 | Palliative (P) | 2017-10-21 | 2017-10-22 | IMATINIB | N | N | 220000450 | IMATINIB |
| 220021616 | 220004088 | 1.66 | 87 | Curative (C) | 2017-10-11 | 2017-10-12 | IMATINIB | null | N | 220001016 | IMATINIB |
| 220021617 | 220004100 | 0 | 0 | Disease modification (D) | 2016-05-03 | 2017-09-10 | Imatinib 400mg | null | N | 220001182 | IMATINIB |
| 220021624 | 220004256 | 1.8 | 0 | Palliative (P) | 2015-10-24 | 2019-01-06 | Imatinib 400mg | N | N | 220004877 | IMATINIB |
| 220021626 | 220004350 | null | null | Disease modification (D) | 2014-05-23 | 2014-05-23 | IMATINIB | null | null | 220007267 | IMATINIB |
| 220021627 | 220004369 | null | 97.3 | Curative (C) | 2014-01-25 | 2014-01-25 | Imatinib 600mg | 2 | N | 220007789 | IMATINIB |
| 220021628 | 220016687 | null | null | Palliative (P) | null | 2017-04-09 | IMATINIB | null | null | 220007957 | IMATINIB |
| 220021629 | 220020580 | 0 | 124.6 | Disease modification (D) | 2015-10-25 | 2016-11-22 | IMATINIB | 02 | N | 220008330 | IMATINIB |
| 220021630 | 220004405 | 1.7 | 95.5 | Disease modification (D) | 2015-09-22 | 2015-09-25 | IMATINIB | null | N | 220008562 | IMATINIB |
| 220021633 | 220004460 | 1.77 | 68.8 | Curative (C) | 2016-02-01 | 2016-03-23 | DA 3+8 | N | N | 220009894 | DA |
| 220021634 | 220004474 | 1.78 | 80.5 | Curative (C) | 2014-09-22 | 2014-11-16 | DA | 02 | N | 220010339 | DA |
| 220021635 | 220004477 | 1.66 | 62.7 | Curative (C) | null | 2017-03-21 | DA 3+8 | N | N | 220010374 | DA |
| 220021636 | 220020590 | -1 | 119 | Palliative (P) | 2017-04-04 | 2018-12-14 | Azacitidine | 01 | N | 220010587 | AZACITIDINE |
| 220021637 | 220004487 | 1.59 | 110.6 | Curative (C) | 2017-09-05 | 2017-09-07 | DA | N | Y | 220010668 | DA |